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Abstract: Radical prostatectomy is a commonly performed procedure for the treatment of 
localized prostate cancer. One of the long-term complications is erectile dysfunction. There is 
little consensus on the optimal management; however, it is agreed that treatment must be prompt 
to prevent fibrosis and increase oxygenation of penile tissue. It is vital that patient expectations 
are discussed, a realistic time frame of treatment provided, and treatment started as close to the 
prostatectomy as possible. Current treatment regimens rely on phosphodiesterase 5 inhibitors as 
a first-line therapy, with vacuum erection devices and intraurethral suppositories of alprostadil 
as possible treatment combination options. With nonresponders to these therapies, intracaver-
nosal injections are resorted to. As a final measure, patients undergo the highly invasive penile 
prosthesis implantation. There is no uniform, objective treatment program for erectile dysfunc-
tion post-radical prostatectomy. Management plans are based on poorly conducted and often 
underpowered studies in combination with physician and patient preferences. They involve the 
aforementioned drugs and treatment methods in different sequences and doses. Prospective 
treatments include dietary supplements and gene therapy, which have shown promise with there 
proposed mechanisms of improving erectile function but are yet to be applied successfully in 
human patients.
Keywords: erectile dysfunction, phosphodiesterase 5 inhibitors, vacuum erection devices, 
intraurethral suppositories, intracavernosal injections
Introduction
Radical prostatectomy (RP) remains the most commonly employed procedure for local-
ized prostate cancer in patients with a life expectancy of at least 10 years.1 More than 
4,000 patients undergo RP yearly in the UK for localised prostate cancer.2 Common 
complications associated with RP include the development of erectile dysfunction 
(ED). ED and reduced sexual satisfaction have a negative impact on quality of life even 
after initial treatment for cancer.3 Potency rates vary greatly between 14% and 90%.1,3 
The reasons for this large discrepancy in rates of post-RP ED relate to variations in the 
nature of the populations studied as well as differences in data collection and reporting. 
Another recurring problem is the lack of an objective, reliable, and universal definition 
of erectile function (EF), both prior to and after surgery.1 Current literature demonstrates 
inconsistency in how to define “normal” EF, and this has obvious consequences when 
discussing management and progress with patients. The percentage of patients who 
develop post-RP ED depends on several factors, including patient age, preoperative 
potency status (baseline EF), comorbidities, extension of nerve-sparing RP (unilateral 
vs bilateral), type of surgery (intra- vs inter- vs extrafascial), surgical technique (open 
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vs laparoscopic vs robot-assisted RP), and level of surgical 
experience.1 Of greater relevance to this review, there is little 
consensus as to the optimal management pathway of post-RP 
ED; this has been the case since the nerve-sparing RP was 
introduced by Walsh et al over 30 years ago.1,3,4 It is evident 
that minimizing and reversing post-RP ED remains a major 
challenge for urologists, and therefore reviewing the manage-
ment options is of great importance. This review provides an 
overview of the management of ED post-RP.
Pathophysiology of erectile  
dysfunction following nerve- 
sparing radical prostatectomy
A thorough understanding of the pathogenesis of post-RP 
ED is required in order to fully comprehend the rationale 
behind different therapies. During sexual stimulation, nitric 
oxide (NO) from the cavernosal nerves is released, leading to 
an increase in oxygenated blood flow to the penis. Vascular 
and sinusoidal forces on the endothelium lead to a sustained 
nitric oxide synthase (eNOS) release from endothelial cells 
(Table 1). This mechanism is crucial for erection prior to 
intercourse as well as the long-term maintenance of corporal 
health. A reduction in tissue oxygenation leads to a decrease 
in NO production, and this in turn leads to inhibition of 
prostaglandin release. This has an important role in protect-
ing smooth muscle through inhibition of accumulation of 
profibrotic substances (such as collagen I and III). Prolonged 
hypoxia will result in connective tissue buildup, which will 
eventually replace more elastic trabecular smooth muscle. 
These fibrotic changes make it increasingly challenging for 
the penis to expand on stimulation through the mechanisms 
described above.5 RP exacerbates these changes or may even 
initiate them in younger patients undergoing the procedure. 
Even in the hands of the most experienced surgeon, a degree 
of cavernosal nerve damage occurs during prostatectomy.6 
The main mechanism through which this is thought to occur 
is neuropraxia. The exact etiology of neuropraxia is a  matter 
of debate, but hypotheses include direct trauma during 
surgery, thermal damage due to electrocautery, cavernous 
nerve ischemia due to vascular injury (such as the accessory 
pudendal arteries), and local inflammatory effects associated 
with the procedure.3,7
Overall, EF is impacted post-RP by interference with the 
nerve function that facilitates cavernosal oxygenation. In 
time, fibrosis ensues, and this is manifested by the presence of 
transforming growth factor β (TGF-β) – a marker of chronic 
inflammation and fibrosis.3 Simultaneously, production of 
antifibrotic mediators prostaglandin E1 (PGE1) and cyclic 
adenosine monophosphate (cAMP) ceases, and there is no 
resultant inhibition of TGF-β1-induced collagen synthesis.9 In 
addition, synthesis of endothelin-1 (ET-1) (a potent constrictor 
of penile smooth muscle) is amplified by TGF-β1 and pro-
longed hypoxia. While neuropraxia is, fortunately, reversible, 
the product of fibrosis, cavernosal smooth muscle apoptosis, 
is not. This is why timely treatment of post-RP ED is vital.3
It is possible that the deposition of collagen is due to cel-
lular apoptosis of smooth muscle (not of the endothelium), 
particularly in the subtunical area, causing dysfunction of the 
veno-occlusive mechanism of the corpus cavernosum. These 
mechanisms underlie the etiology of the massive corporeal 
venous leaks that follow.6 The damage manifests itself as 
chronic ED. To counter the fibrosis, early tissue oxygenation 
is paramount, and this serves as the rationale behind the 
majority of management options.
Managing patient expectations  
and objectives of management
The International Consensus of Sexual Medicine (ICSM) 
recommends the application of psychometric tools to yield 
a better understanding of the patient-specific EF pre- and 
post-RP. Highly recommended psychometric tools are the 
International Index of Erectile Function (IIEF) (Table S1) or 
the Sexual Health Inventory for Men (SHIM) (Table S2), with 
cutoff scores for “normal” EF being 26 and 21, respectively. 
This will help both patients and professionals understand 
how to prevent damage and tackle recovery while reducing 
false expectations. In addition, knowledge of potential use of 
preoperative erectogenic aids is of great value.1 All patients 
should undergo a detailed evaluation to establish their level 
of EF presurgery. This includes applying psychometric tools 
along with a detailed sexual history.5
Patient expectations should be explored prior to discus-
sion of different management approaches and outcomes. 
Expectations for both patients and professionals are usually 
Table 1 Nitric oxide synthase (NOS) subtypes
Type Location Function
endothelial  
NOS/eNOS
vascular endothelial 
cells
vasodilation 
vasoprotection 
Atherosclerosis prevention
inducible  
NOS/iNOS
Macrophages Nonspecific immune defense 
Mediation of inflammation 
Septic shock
Neuronal  
NOS/nNOS
Neuronal tissue Synaptic plasticity 
Blood pressure regulation 
Atypical neurotransmission
Note: Data from.8
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high, with reports of an average of only 50%–60% of patients 
returning to their approximate baseline score at 1 year (based 
on the IIEF score).4 Realistically, a patient will not retain the 
ability to create spontaneous and nocturnal erections within 
the first few months regardless of how aggressive the treat-
ment is. Thus, another important factor in preventing false 
expectations is providing patients with a realistic time frame 
for recovery of EF. Experts suggest a period of 6–36 months 
would be necessary; however, most individuals will experi-
ence functional recovery within 12–24 months post-RP.1,10
Recovery of function can occur only through a rehabili-
tation process that prevents fibrosis and end-organ damage 
while the nerves and vasculature recover. This needs to be 
communicated well to the patient, as many patients will 
become discouraged by the lack of progress.5
It is very important that the partners of patients be 
incorporated in the consultation and treatment process. This 
is in line with recent findings that a divergence in attitude 
and expectations between both partner and patient may 
render the treatment process futile. High expectations might 
cause sexual anxiety in patients who are unable to meet 
their partners’ needs. As such, the presence of partners in 
counseling may prevent this from happening, by encourag-
ing the discussion of frustrations. In addition, cooperative 
partners maintained sexual desire in patients compared with 
noncooperative ones, who created less sexual motivation in 
patients post-RP.11,12
Also worth communicating to the patient are prognostic 
indicators. One excellent prognostic indicator is the ability 
to have either a spontaneous or a pharmacologically assisted 
functional erection within 3 months post-RP.1
Postoperative treatment
Many different treatment strategies have been devised to 
improve EF in post-RP patients. Although there is little con-
sensus with regard to the best strategy, treatment is undoubt-
edly better than leaving the tissue unassisted. Evidence 
suggests that the incidence of veno-occlusive dysfunction 
increases in a time-dependent fashion post-RP. The following 
management options have been listed by the ICSM commit-
tee in combination or as stand-alone therapies: regular oral 
phosphodiesterase type5 inhibitors (PDE5), vacuum erec-
tion devices (VEDs), intraurethral alprostadil suppository 
(MUSE®, Vivus Inc., Mountain View, CA, USA), intracav-
ernosal injections (ICIs), and neuromodulatory agents. The 
ICSM committee is unable to recommend specific, optimal 
rehabilitation regimens, and therefore these therapies are 
utilized differently in practice. Penile implants are reserved 
for a specific cohort of patients when less invasive treatments 
have failed. Evidence-based, expert opinion also supports 
early treatment for better long-term outcomes.13 The litera-
ture emphasizes that any form of rehabilitation or treatment 
should be initiated as close to the surgery as possible.
Phosphodiesterase type 5 inhibitors
As already mentioned, there is evidence to suggest apoptotic 
processes taking place in the smooth muscle of the penis 
following cavernosal nerve injury. Therefore, both smooth 
muscle fibrosis and atrophy in cavernosal tissue may occur 
owing to the cessation of key growth factor production by 
cavernosal nerves. Instead, there is production of proapop-
totic cytokines and reactive oxygen species by damaged 
nerves. Unsurprisingly, cavernosal tissue counteracts this 
mechanism through endogenous production of inducible 
nitric oxide synthase (iNOS) and its secondary messenger, 
cyclic guanosine monophosphate (cGMP). As PDE5 works 
by inhibiting the degradation of cGMP and subsequently 
increasing blood flow to the penis, it has a theoretical applica-
tion in post-RP ED.9 This process will, at least hypothetically, 
yield a higher level of oxygenated blood flow to the corpora 
cavernosa, which in turn is needed for NO production – and 
thus prevention of connective tissue formation. Despite these 
beneficial effects, precautions must be taken when admin-
istering PDE5 in view of the adverse effects of these same 
vasodilatory characteristics on capillary systems running in 
smooth muscle structures in other parts of the body (Table 2). 
Similarly, these same characteristics make their concur-
rent administration with organic nitrates unfeasible. This is 
because when nitrates are given at the same time as PDE5 
inhibitors (PDE5i), there is both an increase in the produc-
tion of cGMP (due to the NO donor) and an inhibition of its 
breakdown (due to the PDE5i) that can lead to a buildup of 
cGMP with pronounced vasodilation and, in some patients, 
hypotension.14 Significant hypotension occurs once again 
Table 2 Common (.1%) side effects of the phosphodiesterase 
type 5 inhibitors
Common side effects Sildenafil Vardenafil Tadalafil
Headache   
Dyspepsia   
Dizziness   
Flushing   
Nasal congestion  
Rhinitis 
Altered vision 
Back pain, myalgia 
Note: Data from.15
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on using vardenafil or tadalafil with α-blockers (Table 3). 
Conclusively, α-blockers are contraindicated.15
There is histological evidence from rat models to sug-
gest improvement of EF and preservation of cavernosal 
smooth muscle integrity after cavernous nerve injury when 
supplemented with PDE5i.16 In a similar animal study, it has 
also been shown that chronic administration of PDE5i limits 
apoptosis by improving the smooth muscle/collagen ratio 
in corporal tissue.5 The animal study looked at resection or 
crush injuries to the cavernosal nerve rather than neuropraxia 
secondary to prostatectomy.5
Evidence is sparse with regard to human studies assessing 
cavernosal tissue before and after treatment with PDE5i. In a 
study by Schwartz et al,17 sildenafil preserved intracorporeal 
smooth muscle after radical retropubic prostatectomy; the 
effect of sildenafil on intracorporeal smooth muscle content 
of post-RP patients was evaluated. Previously potent volun-
teers (n=21) received 50 or 100 mg of sildenafil, respectively, 
every other night for 6 months starting on the day of catheter 
removal. Cavernosal biopsy was performed under local 
anesthesia before the RP procedure and after 6 months had 
elapsed. In the 100 mg group there was a statistically signifi-
cant increase in mean smooth muscle after surgery (42.8% vs 
56.9%, P,0.05) versus no statistically significant change in 
mean smooth muscle in the 50 mg group (51.5% vs 52.7%). 
The major limitation of this study was the lack of a placebo 
group and whether this group would have experienced a 
return of potency.9
In general, PDE5i, eg, sildenafil, are often the first-line 
therapy for patients  postprostatectomy. A comprehensive 
meta-analysis by  Montrosi and McCullough18 looked at 
the role of PDE5i therapy in post-RP patients. The overall 
response rate to therapy was found to be 35% (95% CI [con-
fidence interval]: 24%–48%). This data included patients 
who received different degrees of nerve sparing (NS) during 
surgery. It was concluded that NS is a very important factor 
in determining response rate to PDE5i (NSRP [nerve-sparing 
radical prostatectomy] ranging from 35%–75% vs non-NS 
ranging from 0%–15%); however, not all studies included in 
the meta-analysis commented on the degree of NS. Another 
limitation was the lack of a standard measure of EF used by 
all the studies.3
A prospective, two-center, double-blind, parallel group, 
placebo-controlled randomized controlled trial (RCT) with 
76 patients looked at the efficacy of nightly doses of sildenafil 
in postbilateral nerve-sparing radical prostatectomy (BNSRP) 
patients. Three groups were compared in this study: sildenafil 
50 mg, sildenafil 100 mg, and placebo. The patients were 
administered the drugs on a nightly basis for a total of 36 
weeks followed by an 8-week washout period without any 
erectogenic aid. The first dose was given 4 weeks after sur-
gery. The aim was to compare normalization of spontaneous 
EF by looking at differences in IIEF scores between the three 
groups. Normalization occurred in only 4% of the placebo 
groups (1 in 25 patients) versus 27% (14 in 51 patients, 
P=0.0156) in the sildenafil group. Therefore, it was concluded 
that surgery alone is inferior to surgery plus rehabilitation 
(which includes a PDE5i). A limitation of this study was the 
relatively low number of patients enrolled. A dose-dependent 
improvement in nocturnal penile tumescence and rigidity 
using the Rigiscan device (Timm Medical Technologies, 
Inc., Eden Prairie, MN, USA; a device that measures penile 
tumescence and rigidity continuously) was noted in a suba-
nalysis of the study.19
The largest randomized, placebo-controlled clinical trial20 
of PDE5i in post-RP ED recruited 628 patients post-BNSRP 
with normal preoperative EF. The three groups compared 
were on-demand vardenafil, nightly vardenafil, and placebo. 
This study did not show any significant differences in improv-
ing EF and sexual intercourse completion rates between 
the treatment groups and placebo after the 8-week washout 
period. Similarly, in the open-label phase of this trial, no 
advantage of the treatment arm over placebo was shown.9 
Both studies show conflicting results with neither addressing 
long-term return of function.18,20
There are no approved guidelines on the best approach of 
PDE5i therapy, nor is there evidence to support one particu-
lar program over another.9 In a study by Bannowsky et al,21 
23 patients with preserved nocturnal erections were treated 
with nightly doses of sildenafil (25 mg per day for 52 weeks) 
and then compared with a control group (n=18) who did 
not experience nocturnal erections (documented by use 
of the Rigiscan device). In the sildenafil group, 47% of 
patients achieved and maintained a penile erection sufficient 
for  vaginal intercourse, compared with 28% of controls. 
On-demand, additional doses (50–100 mg) of sildenafil 
were provided, and the baseline potency went up to 86% in 
the sildenafil group compared with 66% in the control one. 
The authors concluded that the selection of patients for 
Table 3 Contraindications of phosphodiesterase inhibitors
Sildenafil Vardenafil Tadalafil
Organic nitrates  
(regular or  
intermittent use)
Nitrates and NO  
(nitric oxide) donors  
(regular or intermittent 
use), α-blockers
Organic nitrates 
(regular or intermittent 
use), α-blockers other 
than 0.4 mg tamsulosin
Note: Data from.14
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sildenafil should be based only on preserved nocturnal 
erections post-RP.9
Avanafil, a recently released PDE5i, has been found par-
ticularly effective in treating ED in post-nerve-sparing RP 
and diabetic patients. It has successfully treated patients who 
had previously undergone failed therapy with other PDE5i 
drugs (sildenafil, tadalafil, vardenafil).22,23
Several studies have been carried out reporting the effec-
tiveness of this new therapy, the most notable of which was by 
Mulhall et al. In this double-blind, parallel study, 298 post-RP 
ED patients were randomized to placebo or avanafil at 100 
and 200 mg. A positive, statistically significant increase in 
IIEF-EF scores was recorded in those patients under both 
doses of avanafil (3.6 at 100 mg, 5.2 at 200 mg) compared 
with the placebo group (0.1) by the end of the 12-week treat-
ment phase of the study (P,0.01). These beneficial results 
were maintained at three primary co-end points, throughout 
measuring the IIEF EF, and were observed in secondary end 
points, measuring other IIEF domains (orgasmic function, 
sexual desire, intercourse, and overall satisfaction). Many 
participants reported improvements using avanafil within 
15–30 minutes, an advantageous early onset characteristic 
caused by the rapid rate of absorption of this drug. It is also 
noteworthy to report that 71.5% of participants had severe 
ED at baseline, before treatment initiation (mean overall 
IIEF-EF domain score was 9.2).23
vacuum erection devices (veDs)
The vacuum erection device (VED) functions by drawing 
blood into the corporal bodies through the use of a manually 
created negative pressure gradient. A constriction ring can 
then be applied to the base of the penis, thereby prevent-
ing venous return and sustaining an erection.2 Although an 
erection that is sufficient for intercourse may be created, it is 
questionable whether this erection will provide sufficient oxy-
gen saturation of the corporal tissue to prevent future fibrosis. 
Many clinicians dismiss this since it has been shown that an 
erection created by a VED consists of 5% arterial blood and 
42% venous blood, and has a SaO
2
 of 76%. This is comparable 
to the SaO
2
 of PGE-1-induced erections of 78.5%. These two 
methods should be considered equal in terms of oxygenation 
potential; this needs to be communicated to patients to aid in 
decision making with regard to management. Evidence from 
a small pilot study suggests that early (1 month postsurgery) 
VED therapy after nerve-sparing RP both improves EF and 
prevents loss of penile length at 3 and 6 months. This is in 
comparison with a group that commenced the VED therapy 
6 months postoperatively. At the last follow-up (on average 
9.5 months post-RP), there was no significant difference in 
EF and penile length between the two groups.5
It should also be noted that VED is more cost effective 
than other therapy options owing to the absence of a marginal 
cost of usage and its long-term viability, with it having an 
approximate life span of five years. In addition, VED has the 
ability to achieve for some individuals an erection sufficient 
for sexual function almost immediately, with minimal side 
effects.3 Furthermore, Vasdev et al exhibited the low cost 
associated with VED (£228) compared with an alprostadil 
injection (£2589) treatment over a 5-year period.24
Evidence has suggested improvements in both sexual 
function and penile length when using VEDs. There is little 
justification for using VED as a monotherapy for post-RP 
patients. Evidence for VED as a complementary therapy 
to PDE5i is promising, particularly when used prior to 
 intercourse. VED offers a noninvasive and cost-effective 
modality for achieving an erection and should be considered 
when discussing treatment options with patients.2
intraurethral suppository – Alprostadil
Alprostadil (MUSE®), a PGE1 analog administered as an 
intraurethral suppository, is thought to increase corporal 
oxygenation by promoting blood flow. Furthermore, PGE1 
is deficient in penile tissues after RP-induced damage, 
and this also serves as a rationale for using alprostadil. In 
post-RP patients experiencing ED, alprostadil has demon-
strated benefits in terms of intercourse success rates, and 
thus improvements in IIEF scores. However, patients have 
reported discomfort and pain associated with treatment. 
Therefore, noncompliance may be a factor in determining 
the cost-effectiveness of this therapy.2
In a prospective randomized penile rehabilitation trial, 
McCullough et al compared the effectiveness of nightly 
intraurethral alprostadil versus 50 mg oral sildenafil citrate 
after NSRP. No statistically significant differences in the IIEF 
erectile function domain and intercourse success rates were 
observed between the two groups. The authors concluded that 
the return of EF with nightly sildenafil citrate and subthera-
peutic intraurethral alprostadil appears to be similar within 
the first year after surgery.25
intracavernosal injections
Intracavernosal injections (ICIs) are among the most estab-
lished methods of producing an erection in any patient with 
ED. Improved knowledge in the physiologic mechanisms 
behind erections has led to a change from alprostadil-based 
ICIs to a TriMix (papaverine, phentolamine, and PGE1). 
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Evidence suggests that for nonresponders to PDE5is, ICIs 
are effective in restoring EF. It has potential as a therapeutic 
strategy in nonresponders; however, psychosexual concerns 
associated with self-administrated penile injections should 
be taken into consideration when decision-making with 
patients.2
Alprostadil-based ICIs often cause penile pain that may 
lead to high discontinuation rates. Therefore, it would be 
wise to reserve ICI treatment for patients in whom PDE5i are 
considered ineffective. However, there is emerging evidence 
that TriMix is associated with less pain (both after injection 
and during erections) than alprostadil-based ICIs.13
Penile prosthesis implantation
This invasive surgical approach is limited for use in patients 
with end-stage ED following RP. ICSM committee experts 
concluded that penile prostheses should be indicated as a 
third-line treatment.26 Results from a large epidemiological 
study has highlighted that penile prostheses are scarcely 
requested after prostate cancer treatment.27 This is not due to 
a poor outcome after implant treatment as the literature has 
shown quite the opposite. Penile implants have been associ-
ated with technical feasibility, safety, high efficacy as an ED 
treatment with higher treatment satisfaction compared with 
PDE5i or ICI in both patients and partners.
In a study by Megas et al, the outcome of penile prosthe-
sis surgery in comparison with PDE5i in men with ED post-
NSRP as an early penile intervention therapy was assessed. 
A total of 153 patients fulfilled the inclusion criteria of the 
study, and 69 (45%) presented with post-radical retropubic 
prostatectomy erectile dysfunction 6 months after surgery. 
Fifty four of these patients were disease-free and were split 
into two groups: Tadalafil three times per week or penile 
prosthesis implantation. All patients were evaluated using 
the IIEF questionnaire preoperatively and at 6, 12, and 24 
months postoperatively. In both groups, there was a sig-
nificant reduction of the IIEF score preoperative values to 
the first measurement after surgery. However, the degree 
of change of IIEF scores from immediately after surgery 
to 2 years was greater in the penile prosthesis group than 
the tadalafil group (20.4±1.3 vs 8.1±2.4, P,0.001). Penile 
prosthesis was superior to oral treatment in terms of the 
following parameters: frequency, firmness, penetration 
ability, maintenance, and erection confidence. The authors 
concluded that the concept of early penile prosthesis 
intervention should be considered for all patients who 
suffer from post-RP ED. Limitations include a relatively 
small cohort of patients and a lack of discussion about 
the potential cost of surgery in comparison with that of 
pharmacological treatment.28
Discontinuation of treatment
It is important to note that significant rates of discontinua-
tion have been exhibited by patients who have undertaken 
each of the different modes of therapies displayed above. 
Discontinuation occurs from a multitude of causes that 
differ depending on the treatment taken; many studies 
have probed into these and estimated the corresponding 
rates of discontinuation for each therapy using various 
regimens (Table 4).
Table 4 Rates and reasons for discontinuation for different treatment modalities
Treatment Incidences of discontinuation Reasons for discontinuation
Phosphodiesterase type 5  
inhibitor-(PDe5i)29
An overall 72.6% discontinuation rate found  
at an 18-month follow-up for patients using  
both daily PDe5i and as needed PDe5i therapy
effect below expectations 
Loss of interest in sex in either partner or patients 
High cost 
Side effects of treatment
vacuum erection Devices  
(veDs)30
20% (28/113) discontinuation after 1 year of veD  
use. This increased to 38% (43/113) after  
5 years of treatment
Loss of interest in sex 
Urinary incontinence 
Loss of libido 
Cardiovascular and CNS effects (seen only in the 5-year 
discontinuers)
intraurethral Suppository31 32% (18/56) discontinuation rate in patients  
treated with MUSe® before the end of a 9-month  
treatment period
Lack of efficacy/insufficient erections 
Reduced sexual interest 
Adverse effects of the medication (urethral burning or pain)
intracavernosal injections  
(iCis)32
52% (53/102) of patients discontinued iCi therapy  
after a mean use of 14.5 months
Insufficient erections 
Preference for oral therapy 
Fear of injections 
Troublesome procedure 
Priapism 
Return of natural erection
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Psychological and sexual counseling
The ICSM committee recommends that clinicians should 
communicate the essential elements of the pathophysiology 
of post-RP ED1,2 and that penile rehabilitation may have 
potential benefits for the patient.13 In a small prospective 
study by Titta et al, a small cohort of patients who completed 
the IIEF one month after non-NSRP were shown how to 
use ICI. The patients were later randomized to either ICI 
treatment alone or a group who received PGE1-ICI therapy 
and sexual counseling for 18 consecutive months. The study 
showed that men who were in the latter group reported the 
best quality in all IIEF domains, the lowest discontinu-
ation rate, and the highest degree of couple satisfaction 
compared with the men who did not receive counseling in 
combination with the ICI therapy. The counseling reduced 
the number of patients reporting lack of sexual spontaneity, 
dissatisfaction, and fear of needles.13,33 This highlights the 
major importance of counseling as an effective contribu-
tion to ameliorating treatment efficacy as well as patient 
compliance, and as such lowering the discontinuation rates 
mentioned previously.33
Practical therapeutic approaches
The UK has yet to devise a national strategy for treatment of 
post-RP ED, taking into consideration the literature, licensed 
treatments, and cost-effectiveness. This particular approach 
is taken from the Baylor College of Medicine. Their protocol 
revolves around the use of PDE5i daily at a low dose, with 
the regimen of treatment aptly starting before the surgery 
and continuing shortly after.3 Furthermore, this protocol in 
its use of PDE5i has instructed doses and combinations that 
recognize results found in the literature of proven efficacy. 
The oral route of treatment in the early portion of the study 
considers patient convenience and comfort.
Moskovic et al34 instructs patients to take 25 mg of 
sildenafil every night in addition to 250 µg alprostadil urethral 
suppositories three times per week. The treatment regimen 
begins up to 1 week prior to surgery. Patients are instructed 
to restart 25 mg of sildenafil nightly 3 days post-RP and add 
250 µg alprostadil suppositories three times per week once 
the catheter has been removed. One month after RP, the 
patients are seen in clinic, where the response to therapy is 
assessed. Patients are encouraged to engage in sexual activity 
if medically cleared. Alprostadil is dose-titrated if indicated, 
side effects are established, the importance of compliance 
is reviewed, and patients are asked about spontaneous EF. 
Finally, all patients are introduced to VED usage. Patients 
are instructed to use a VED at least 10 minutes a day. Three 
months after RP, ICIs are introduced in the EF preservation 
program for patients who are not responding to the com-
bination of  sildenafil, MUSE and VED. The patients are 
instructed to self-inject a TriMix 3 days per week in addi-
tion to the nightly 25 mg of sildenafil and the daily VED 
therapy. These particular patients are seen on a monthly basis 
to reestablish whether a combination therapy of sildenafil, 
VEDs, and alprostadil suppositories may be reintroduced 
(Figure 1).
Pre-RP clinical visit
Pre-RP protocol
Post-RP protocol
Clinical visit 3 months
Non-responder protocol
Responder protocol
Quarterly clinical visit
Monthly
Quarterly clinical visit
Clinical visit 1 month
Determine: baseline IIEF, co-
morbidities for ED risk factors,
history of EF and other treatment
Discuss: sexual intercourse after
surgery and relevant physiology
Nighty sildenafil (25 mg) up to
1 week
MUSE (250 µg) 3×/week up to
1 week before RP
Continue sildenafil 3 days after RP
Continue MUSE treatment
Continuation of treatment
Assess response to therapy
Dose titrate MUSE if non-responsive
start VED usage  (10 minutes daily)
Assess response to sildenafil and
MUSE
Nightly sildenafil (25 mg)
ICI 3 days/week (TRIMIX)
VED 7 days/week (10 m)
Nightly sildenafil (25 mg)
MUSE 3 days/week (250 mcg)
VED 7 days/week (>=10 m)
Assess response to sildenafil
and MUSE
If patient responds
Nightly sildenafil (25 mg)
ICI 3 days/week
VED 7 days/week
Assess response to ICI
Visits are continued for 18–24 months after surgery to 
give the patient ample opportunity to respond to therapy.
In the case of the failure of these options,
penile prosthesis implantation is indicated
Re-assess sildenafil/MUSE
response without ICI
Figure 1 A suggested approach to management of erectile dysfunction in the 
context of a radical prostatectomy.
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All clinical visits also involved the following 
procedures:
•	 Reviewing the importance of compliance
•	 Determining side effects
•	 Inquiring about spontaneous EF
•	 Encouraging continuation of erectile preservation (edu-
cating the patient on the importance of compliance to the 
protocol and to the dosing regimen).
Future treatments
Dietary
A number of trials (including two randomized, placebo-
 controlled trials) have looked into the combination of 
l-arginine and Pycnogenol (extract of the French pine tree 
Pinus pinaster) with promising results. l-arginine has been 
shown to increase levels of eNOS and Pycnogenol, an anti-
oxidant that stimulates the conversion of l-arginine into NO 
via eNOS. The trials demonstrated increased patient-reported 
EF during 1 month of supplementation without the use of 
on-demand therapies (eg, PDE5i). The major limitation is that 
the trials were designed for non-radical prostatectomies and 
therefore more appropriately designed randomized controlled 
trials involving patient post-RP are required.4
Care should be taken when discussing dietary supplements, 
as there have been a number of commercially available supple-
ments promoted as a means of natural enhancement. The lack 
of efficacy studies should be highlighted to the patient.4
Gene therapy
Despite the numerous aforementioned options of manage-
ment that can be used in treating ED post-RP and their 
relatively high success rates, some patients do not have a 
successful outcome. As such, the feasibility of gene therapy 
has been researched in the past ten years. Its functionality 
centers on the operation of three physiological functions 
whose enhancement restores erectile activity:35
•	 Enhancing NO production or NO-medicated signaling 
pathways (restoration of endogenous NO synthesis and/
or enhancement of the NO-related cascade in the penis). 
This can take place through the injection of recombinant 
adenovirus containing the eNOS gene into the corpus 
cavernosum, resulting in increased eNOS transgene 
expression and cGMP levels. This has also been found 
to enhance intracavernosal pressure (ICP) increase in 
response to cavernous nerve stimulation. In addition to 
eNOS, gene delivery of other nitric oxide synthase (NOS) 
subtypes such as nNOS (neuronal NOS) and iNOS into 
the penis also improves EF.
•	 Enhancing growth factor-mediated nerve regeneration. 
This process can be mediated through increasing the 
levels of numerous growth factors, one of which is the 
promising Neurotrophin-3 (NT3). NT3 was found to 
increase fiber growth in male rat major pelvic ganglia 
cultures more than other growth factors. This result was 
followed up with an experiment that compared HSV 
(Herpes simplex virus) vector mediated NT3 versus HSV 
vector expressing Beta galactosidase postinjection into 
cavernous nerve sheaths. Data measurements collected 
four weeks later suggest that NT3 might assist regenera-
tion/repair/survival and increased nNOS expression in 
pelvic ganglion neurons to restore EF in diabetic rats. 
This was supported with the fact that the mean number 
of NOS positive neurons per section in the NT3 group 
was much greater than in the β galactosidase one and the 
former group achieved maximal ICP. Similar beneficial 
results have been displayed with other growth factors like 
GDNF (Glial cell line-derived neurotrophic factor), NTN 
(neurturin), BDNF (brain derived neurotrophic factor), 
IGF1 (insulin-like growth factor 1), and VEGF (vascular 
endothelial growth factor).
•	 Enhancing potassium ion channel activity and conduc-
tance in the cavernous smooth muscle. Potassium ion 
channels stabilize the membrane potential and reduce the 
excitability of nerves and muscle cells, including smooth 
muscle cells in the penis.
Penile corporeal muscle relaxation occurs with decrease 
in calcium levels due to hyperpolarization of smooth muscle. 
This takes place because of membrane potential depolariza-
tion, an increase in cystolic calcium ion levels, and/or NO/
cGMP-mediated mechanisms that activate calcium-activated 
potassium channels. Studies36,37 have revolved around the 
gene transfer of naked hSlo cDNA that encodes the human 
BK channel (potassium channels characterized by their large 
conductance of potassium ions [K+] through cell membranes) 
α-subunit to intracavernosum. Halo cDNA is inserted into a 
mammalian plasmid, after which its expression is driven by 
a promoter. The plasmid is designed to replicate the inserted 
DNA sequence. The plasmid with its desired DNA sequence 
enters the nucleus of the host cell and transcribes the desired 
mRNA strand, producing functional BK channel proteins. 
Significant elevation of ICP in response to cavernous nerve 
stimulation was also noticed in aged or diabetic rats that had 
plasmid-containing Halo DNA injected intracavernously.
Great promise has been shown with these approaches and 
their potential has been exhibited on rat models; however, 
concern remains with the safety of gene therapy and its 
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clinical translation to patients. This is best resembled with the 
use of viral delivery vehicles to transfer the genes. Viruses 
have acquired efficient methods to deliver their own genetic 
material to cells and can be readily produced and purified 
for in vivo gene transfer in contrast to nonviral methods that 
have production limited to sufficient quantities of DNA for 
transduction. However, this method incorporates a high level 
of risk owing to endogenous viral recombination, cancer 
development, and immunological reactions.38
Conclusion
ED is a reality for many men post-RP. One significant 
obstacle is the lack of a standardized, objective, universal 
definition to accurately define baseline EF and postoperative 
ED. This makes it challenging to tailor treatment, manage 
expectations, and also monitor progress in patients who suffer 
from post-RP ED. Nevertheless, treatment remains undoubt-
edly superior to leaving the tissue without intervention.
Treatment and recovery are possible, but the process of 
rehabilitation should be initiated as early as catheter removal 
or during the first month post-RP.13 There is evidence sup-
porting this notion and suggesting benefits in early postop-
erative treatment with PDE5i as this may certainly lead to 
positive long-term results in terms of recovery of EF. Patient 
expectations and wishes should be discussed; this includes 
achieving a good understanding of baseline EF. On-demand 
PDE5i (sildenafil, tadalafil, and vardenafil) may prove useful 
in patients who have undergone NSRP (there are no definitive 
conclusions to suggest greater, long-term benefits of daily 
PDE5i use versus an on-demand use in post-RP patients).2 
Although the rationale in using a PDE5i in the rehabilitation 
process may seem reasonable, further research is needed 
to optimize prognoses of patients. This includes deciding 
when to start, the dosage regimen prescribed, total period of 
treatment, suitability of patients, and which drug is best to 
use.9 Although numerous animal studies have suggested that 
PDE5i can prevent smooth muscle apoptosis and fibrosis, this 
is yet to be established in human trials. ICIs should mainly be 
considered in patients nonresponsive to PDE5i in combina-
tion with VEDs and alprostadil suppository.
Although penile pain associated with self-administered 
injections may diminish over time, TriMix injections may 
lead to better compliance, as they are associated with less 
pain. Psychological and sexual counseling has shown addi-
tional improvements for rehabilitation and treatment strate-
gies of post-RP ED; it is recommended by both the ICSM and 
published literature. Finally, in a reserved group of patients 
with evidence of end-stage ED, penile prosthesis should 
also be a point of discussion, especially when less invasive 
treatment has failed.
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Supplementary materials
Table S1 Patient questionnaire based on international index of erectile Function (iieF) and its clinical application
INTERNATIONAL INDEX  
OF ERECTILE FUNCTION (IIEF) 
 
 
 
 
 
Patient Questionnaire
HOSPiTAL NUMBeR (iF KNOwN) 
NAMe ___________ 
DATe OF BiRTH / / AGe
ADDReSS ___________________
 ___________________
 ___________________
TeLePHONe ___________________
These questions ask about the effects that your erection problems have had on your sex life over the last four weeks. Please try to answer the ques-
tions as honestly and as clearly as you are able. Your answers will help your doctor to choose the most effective treatment suited to your condition. in 
answering the questions, the following definitions apply:
– sexual activity includes intercourse, caressing, foreplay and masturbation
– sexual intercourse is defined as sexual penetration of your partner
– sexual stimulation includes situation such as foreplay, erotic pictures etc
– ejaculation is the ejection of semen from the penis (or the feeling of this)
– orgasm is the fulfilment or climax following sexual stimulation or intercourse
Over the past 4 weeks Please check one box only
Q1 How often were you able to get an erection during sexual activity? 0 No sexual activity 
1 Almost never or never 
2 A few times (less than half the time) 
3 Sometimes (about half the time) 
4 Most times (more than half the time) 
5 Almost always or always
Q2 when you had erections with sexual stimulation, how often were  
your erections hard enough for penetration?
0 No sexual activity 
1 Almost never or never 
2 A few times (less than half the time) 
3 Sometimes (about half the time) 
4 Most times (more than half the time) 
5 Almost always or always
Q3 when you attempted intercourse, how often were you able to  
penetrate (enter) your partner?
0 Did not attempt intercourse 
1 Almost never or never 
2 A few times (less than half the time) 
3 Sometimes (about half the time) 
4 Most times (more than half the time) 
5 Almost always or always
Q4 During sexual intercourse, how often were you able to maintain  
your erection after you had penetrated (entered) your partner?
0 Did not attempt intercourse 
1 Almost never or never 
2 A few times (less than half the time) 
3 Sometimes (about half the time) 
4 Most times (more than half the time) 
5 Almost always or always
Q5 During sexual intercourse, how difficult was it to maintain your  
erection to completion of intercourse?
0 Did not attempt intercourse 
1 Extremely difficult 
2 Very difficult 
3 Difficult 
4 Slightly difficult 
5 Not difficult
Q6 How many times have you attempted sexual intercourse? 0 No attempts 
1 One to two attempts 
2 Three to four attempts 
3 Five to six attempts 
4 Seven to ten attempts 
5 eleven or more attempts
(Continued)
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INTERNATIONAL INDEX OF ERECTILE FUNCTION (IIEF)
Guidelines on Clinical Application of IIEF Patient Questionnaire
Table S1 (Continued)
Q7 when you attempted sexual intercourse, how often was it  
satisfactory for you?
0 Did not attempt intercourse 
1 Almost never or never 
2 A few times (less than half the time) 
3 Sometimes (about half the time) 
4 Most times (more than half the time) 
5 Almost always or always
Q8 How much have you enjoyed sexual intercourse? 0 No intercourse 
1 No enjoyment at all 
2 Not very enjoyable 
3 Fairly enjoyable 
4 Highly enjoyable 
5 very highly enjoyable
Q9 when you had sexual stimulation or intercourse, how often did  
you ejaculate?
0 No sexual stimulation or intercourse 
1 Almost never or never 
2 A few times (less than half the time) 
3 Sometimes (about half the time) 
4 Most times (more than half the time) 
5 Almost always or always
Q10 when you had sexual stimulation or intercourse, how often did  
you have the feeling of orgasm or climax?
1 Almost never or never 
2 A few times (less than half the time) 
3 Sometimes (about half the time) 
4 Most times (more than half the time) 
5 Almost always or always
Q11 How often have you felt sexual desire? 1 Almost never or never 
2 A few times (less than half the time) 
3 Sometimes [about half the time) 
4 Most times (more than half the time) 
5 Almost always or always
Q12 How would you rate your level of sexual desire? 1 very low or none at all 
2 Low 
3 Moderate 
4 High 
5 very high
Q13 How satisfied have you been with your overall sex life? 1 Very dissatisfied 
2 Moderately dissatisfied 
3 Equally satisfied and dissatisfied 
4 Moderately satisfied 
5 Very satisfied
Q14 How satisfied have you been with your sexual relationship with  
your partner?
1 Very dissatisfied 
2 Moderately dissatisfied 
3 Equally satisfied and dissatisfied 
4 Moderately satisfied 
5 Very satisfied
Q15 How do you rate your confidence that you could get and keep  
an erection?
1 very low 
2 Low 
3 Moderate 
4 High 
5 very high
Background
The 15-question international index of erectile Function (iieF) Questionnaire is a validated, multidimensional, self-administered investigation that 
has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0–5 is awarded to each 
of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse 
satisfaction.
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Function 
Domain
Maximum  
Score Possible
Mean Scores
Controls Patients
A. erectile Function (Q1,2,3,4,5,15) 30 25.8 10.7
B. Orgasmic Function (Q9,10) 10 9.8 5.3
C. Sexual Desire (Q11,12) 10 7.0 6.3
D. intercourse Satisfaction (Q6,7,8) 15 10.6 5.5
e. Overall Satisfaction (Q13,14) 10 8.6 4.4
in a recent study(1), the iieF Questionnaire was tested in a series of 111 men with sexual dysfunction and 109 age-matched, normal volunteers. The 
following mean scores were recorded:
Clinical Application
IIEF assessment is limited by the superficial assessment of psychosexual background and the very limited assessment of partner relationship, both 
important factors in the presentation of male sexual dysfunction. Analysis of the questionnaire should, therefore, be viewed as an adjunct to, rather 
than a substitute for, a detailed sexual history and examination. The following guidelines may be applied:
1.  Patients with low iieF scores (,14 out of 30) in Domain A (Erectile Function) may be considered for a trial course of therapy with Sildenafil unless 
contraindicated. Specialist referral is indicated if this is unsuccessful.
2. Patients demonstrating primary orgasmic or ejaculatory dysfunction (Domain B) should be referred for specialist investigation.
3. Patients with reduced sexual desire (Domain C) require testing of blood levels of androgen and prolactin.
4.  Psychosexual counselling should be considered if low scores are recorded in Domains D and e but there is only a moderately lowered score  
(14 to 25) in Domain A.
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1. How do you rate your  
confidence that you could  
get and keep an erection?
Very Low Low Moderate HigH Very HigH
1 2 3 4 5
2. when you had erections  
with sexual stimulation, how  
often were your erections  
hard enough for penetration  
(entering your partner)?
No SexuaL  
actiVity
aLMoSt NeVer  
or NeVer
a Few tiMeS 
(MucH LeSS  
tHaN HaLF  
tHe tiMe) 
SoMetiMeS  
(about HaLF  
tHe tiMe)  
MoSt TiMeS  
(MucH More  
tHaN HaLF  
tHe tiMe) 
aLMoSt  
aLwayS or 
aLwayS
0 1 2 3 4 5
3. During sexual intercourse, 
how often were you able  
to maintain your erection  
after you had penetrated  
(entered) your partner?
did Not  
atteMpt  
iNtercourSe
aLMoSt NeVer  
or NeVer
a Few tiMeS  
(MucH LeSS  
tHaN HaLF  
tHe tiMe) 
SoMetiMeS  
(about HaLF  
tHe tiMe) 
MoSt tiMeS  
(MucH More  
tHaN HaLF  
tHe tiMe)
aLMoSt  
aLwayS or 
aLwayS
0 1 2 3 4 5
4. During sexual intercourse, 
how difficult was it to  
maintain your erection to  
completion of intercourse?
did Not  
atteMpt  
iNtercourSe
extreMeLy  
diFFicuLt
Very 
diFFicuLt
diFFicuLt SLigHtLy  
diFFicuLt
Not 
diFFicuLt
0 1 2 3 4 5
5. when you attempted  
sexual intercourse, how often  
was it satisfactory for you?
Did Not  
atteMpt  
iNtercourSe
aLMoSt NeVer  
or NeVer
A Few tiMeS 
(MucH LeSS  
tHaN HaLF  
tHe tiMe)
SoMetiMeS  
(about HaLF  
tHe tiMe) 
MoSt tiMeS  
(MucH More  
tHaN HaLF  
tHe tiMe)
aLMoSt  
aLwayS or 
aLwayS
0 1 2 3 4 5
Table S2 Sexual Health inventory for Men (SHiM)
SEXUAL HEALTH INVENTORY FOR MEN (SHIM)
PATIENT NAME: ––––––––––––––––––––––– TODAY’S DATE: –––––––––––––––––––––
PATIENT INSTRUCTIONS
Sexual health is an important part of an individual’s overall physical and emotional well-being. erectile dysfunction, also known as impotence, is one 
type of very common medical condition affecting sexual health. Fortunately, there are many different treatment options for erectile dysfunction. This 
questionnaire is designed to help you and your doctor identify if you may be experiencing erectile dysfunction. if you are, you may choose to discuss 
treatment options with your doctor.
each question has several possible responses. Circle the number of the response that best describes your own situation. Please be sure that you 
select one and only one response for each question.
OVER THE PAST 6 MONTHS:
Add the numbers corresponding to questions 1–5.      TOTAL: ______________
The Sexual Health Inventory for Men further classifies ED severity with the following breakpoints:
1–7 Severe ED 8–11 Moderate ED 12–16 Mild to Moderate ED 17–21 Mild ED
Reference
1. Rosen R, Riley A, Wagner G, Osterloh I, Kirkpatrick J, Mishra A. The 
international index of erectile function (IIEF): a multidimensional 
scale for assessment of erectile dysfunction. Urology. 1997;49(6): 
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